These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 28638852)

  • 21. Balance performance in three forms of multiple sclerosis.
    Soyuer F; Mirza M; Erkorkmaz U
    Neurol Res; 2006 Jul; 28(5):555-62. PubMed ID: 16808889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The MRZ reaction in primary progressive multiple sclerosis.
    Hottenrott T; Dersch R; Berger B; Rauer S; Huzly D; Stich O
    Fluids Barriers CNS; 2017 Feb; 14(1):2. PubMed ID: 28166789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The MRI central vein marker; differentiating PPMS from RRMS and ischemic SVD.
    Samaraweera APR; Falah Y; Pitiot A; Dineen RA; Morgan PS; Evangelou N
    Neurol Neuroimmunol Neuroinflamm; 2018 Nov; 5(6):e496. PubMed ID: 30345329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impairment in Respiratory Function Contributes to Olfactory Impairment in Amyotrophic Lateral Sclerosis.
    Günther R; Schrempf W; Hähner A; Hummel T; Wolz M; Storch A; Hermann A
    Front Neurol; 2018; 9():79. PubMed ID: 29535673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limb apraxia in multiple sclerosis: prevalence and impact on manual dexterity and activities of daily living.
    Kamm CP; Heldner MR; Vanbellingen T; Mattle HP; Müri R; Bohlhalter S
    Arch Phys Med Rehabil; 2012 Jun; 93(6):1081-5. PubMed ID: 22464095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Income in Multiple Sclerosis Patients with Different Disease Phenotypes.
    Kavaliunas A; Manouchehrinia A; Danylaite Karrenbauer V; Gyllensten H; Glaser A; Alexanderson K; Hillert J
    PLoS One; 2017; 12(1):e0169460. PubMed ID: 28081163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olfactory function in patients with multiple sclerosis: a diffusion tensor imaging study.
    Erb K; Bohner G; Harms L; Goektas O; Fleiner F; Dommes E; Schmidt FA; Dahlslett B; Lüdemann L
    J Neurol Sci; 2012 May; 316(1-2):56-60. PubMed ID: 22341621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.
    Montalban X; Sastre-Garriga J; Filippi M; Khaleeli Z; Téllez N; Vellinga MM; Tur C; Brochet B; Barkhof F; Rovaris M; Miller DH; Polman CH; Rovira A; Thompson AJ
    Mult Scler; 2009 Dec; 15(12):1459-65. PubMed ID: 19995843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis.
    Boppana S; Mindur JE; Balashov KE; Dhib-Jalbut S; Ito K
    J Neuroimmunol; 2013 Dec; 265(1-2):68-74. PubMed ID: 24200257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.
    Saidha S; Syc SB; Durbin MK; Eckstein C; Oakley JD; Meyer SA; Conger A; Frohman TC; Newsome S; Ratchford JN; Frohman EM; Calabresi PA
    Mult Scler; 2011 Dec; 17(12):1449-63. PubMed ID: 21865411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of cognition, quality of life, and fatigue on olfactory function in patients with multiple sclerosis.
    Acikgoz M; Piri Cinar B; Aciman Demirel E; Celebi U; Cekic S; Elicora S; Atasoy HT
    Clin Neurol Neurosurg; 2023 Jun; 229():107739. PubMed ID: 37146370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olfactory bulb volume and olfactory function in patients with multiple sclerosis.
    Goektas O; Schmidt F; Bohner G; Erb K; Ludemann L; Dahlslett B; Harms L; Fleiner F
    Rhinology; 2011 Jun; 49(2):221-6. PubMed ID: 21743881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive performance profile in different phenotypes of MS with cognitive complaints.
    Rosti-Otajärvi E; Ruutiainen J; Huhtala H; Hämäläinen P
    Mult Scler Relat Disord; 2014 Jul; 3(4):463-72. PubMed ID: 25877058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course.
    Silversides JA; Heggarty SV; McDonnell GV; Hawkins SA; Graham CA
    Mult Scler; 2004 Apr; 10(2):149-52. PubMed ID: 15124759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression rates and sample size estimates for PPMS based on the CLIMB study population.
    Raghavan K; Healy BC; Carruthers RL; Chitnis T
    Mult Scler; 2015 Feb; 21(2):180-8. PubMed ID: 25070676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry.
    Jasperse B; Jakobs C; Eikelenboom MJ; Dijkstra CD; Uitdehaag BM; Barkhof F; Polman CH; Teunissen CE
    J Neurol; 2007 May; 254(5):631-7. PubMed ID: 17415509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum NSE level and disability progression in multiple sclerosis.
    Koch MW; George S; Wall W; Wee Yong V; Metz LM
    J Neurol Sci; 2015 Mar; 350(1-2):46-50. PubMed ID: 25686504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression.
    Mancuso R; Hernis A; Agostini S; Rovaris M; Caputo D; Clerici M
    J Transl Med; 2015 May; 13():148. PubMed ID: 25947625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.